Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Warkentin, J. Kelton, J. Kelton (1996)
A 14-year study of heparin-induced thrombocytopenia.The American journal of medicine, 101 5
R. Levine, D. Mccollum, M. Hursting (2006)
How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?Chest, 130 3
A. Vannucchi, T. Barbui (2007)
Thrombocytosis and thrombosis.Hematology. American Society of Hematology. Education Program
M. Randi, M. Putti, M. Scapin, E. Pacquola, F. Tucci, C. Micalizzi, L. Zanesco, F. Fabris (2006)
Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.Blood, 108 10
C. Pouplard, M. May, S. Régina, M. Marchand, J. Fusciardi, Y. Gruel (2005)
Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodiesBritish Journal of Haematology, 128
G. Spectre, Yossi Kalish, L. Schliamser, D. Varon (2008)
Heparin‐induced thrombocytopenia in myeloproliferative disorders: A rare or under‐diagnosed complication?American Journal of Hematology, 83
C. Kitchens (2004)
Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin‐induced thrombocytopeniaAmerican Journal of Hematology, 76
T. Warkentin, R. Roberts, J. Hirsh, J. Kelton (2003)
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.Archives of internal medicine, 163 20
E. Baxter, L. Scott, P. Campbell, C. East, N. Fourouclas, S. Swanton, G. Vassiliou, A. Bench, E. Boyd, N. Curtin, M. Scott, W. Erber, A. Green (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 365
T. Warkentin (2003)
Heparin‐induced thrombocytopenia: pathogenesis and managementBritish Journal of Haematology, 121
Gregory Lo, D. Juhl, T. Warkentin, C. Sigouin, P. Eichler, A. Greinacher (2006)
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 4
(2005)
Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia
J. Vardiman, N. Harris, R. Brunning (2002)
The World Health Organization (WHO) classification of the myeloid neoplasms.Blood, 100 7
M. Randi, F. Stocco, C. Rossi, T. Tison, A. Girolami (1991)
Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases).Journal of medicine, 22 4-5
P. Prandoni, S. Siragusa, B. Girolami, F. Fabris (2005)
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.Blood, 106 9
H. Iland, J. Laszlo, P. Peterson, S. Murphy, J. Briére, A. Weinfeld, Rosenthal Ds, Landaw Sa, Ellis Jt, M. Silverstein (1983)
Essential thrombocythemia: clinical and laboratory characteristics at presentation.Transactions of the Association of American Physicians, 96
T. Warkentin (2006)
Think of HIT when thrombosis follows heparin.Chest, 130 3
J. Briere (2006)
Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.Seminars in thrombosis and hemostasis, 32 3
M. Denninger, Yasmine Chaït, N. Casadevall, S. Hillaire, M. Guillin, A. Bezeaud, S. Erlinger, J. Briére, D. Valla (2000)
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factorsHepatology, 31
P. Eichler, Ulrich Budde, S. Haas, Hartmut Kroll, R. Loreth, O. Meyer, U. Pachmann, Bernd Pötzsch, A. Schabel, D. Albrecht, A. Greinacher (1999)
First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISAThrombosis and Haemostasis, 81
D. Valla (2003)
The diagnosis and management of the Budd‐Chiari syndrome: Consensus and controversiesHepatology, 38
Background: Philadelphia-negative myeloproliferative disorders (Ph-MPD) are common causes of unusual splanchnic or cerebral vein thrombosis, which is treated with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Heparin-induced thrombocytopenia (HIT) is a dangerous potential complication of this therapy, but it has rarely been reported in Ph-MPD. Patients and Methods: We retrospectively reviewed clinical records of 29 patients with Ph-MPD who have been treated with UFH or LMWH for unusual splanchnic or cerebral vein thrombosis (3 cerebral sinus, 6 portal and 20 hepatic vein). The goal of the study was to determine the occurrence of new thrombotic events during heparin therapy secondary to HIT (HITT). Results: During heparin therapy, 5 out of the 29 patients (17%) developed a new thrombotic episode (pulmonary embolism) with a high clinical probability of HIT based on the 4 T’s score even though not all the patients developed ‘true’ thrombocytopenia. A diagnosis of HIT was established in 2 patients (6.8%) through the presence of heparin-related antibodies. Conclusions: Ph-MPD patients on heparin warrant careful monitoring and HIT has to be suspected whenever platelet counts drop or a new thrombosis is detectable.
Acta Haematologica – Karger
Published: Jan 1, 2010
Keywords: JAK2 mutation; Essential thrombocythemia; Unusual splanchnic or cerebral vein thrombosis; Heparin-induced thrombocytopenia; Polycythemia vera
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.